New hope for hard-to-treat lymphoma: triple-drug attack tested in 80 patients
NCT ID NCT07184788
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a combination of three drugs (Glofitamab, Polatuzumab vedotin, and GemOx) as an initial treatment for people with aggressive B-cell lymphoma whose cancer did not respond to prior therapy or has returned. About 80 adults will take part to see if the combination is safe and effective at shrinking or eliminating tumors. The goal is to improve response rates and survival, but ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.